Xiang Wang

TL;DR: An approach was developed that allows the screening of an invariant chain-complementary DNA fusion library in a genetically engineered cell line expressing the essential components of the major histocompatibility complex (MHC) class II processing and presentation pathway, which led to the identification of a mutated form of human CDC27 which gave rise to an HLA-DR4-restricted melanoma antigen.

TL;DR: Results suggested that NY-ESO-1-specific DP4-restricted CD4+ T cells were closely associated with NY- ESO-2-specific Ab observed in melanoma patients and might play an important role in providing help for activating B cells for NY-esO- 1- specific Ab production.

TL;DR: It is proposed that Mediator's structural pliability enables it to integrate and transmit regulatory signals and act as a functional, rather than an architectural bridge, between promoters and enhancers.

TL;DR: The identification of MHC class II-restricted T cell epitopes from NY-ESO-1 provide new opportunities for developing more effective vaccine strategies by using tumor-specific CD4+ T cells.

TL;DR: This represents the first demonstration that a fusion protein resulting from a chromosomal rearrangement in tumor cells serves as an immune target recognized by CD4+ T cells.